Immunic has announced the appointment of Erik Lundgren, a former Genentech executive, as its new Chief Executive Officer, tasked with advancing the company's Phase 3 MS trials.

Immunic reported a GAAP EPS of -$1.08, missing analyst expectations by $0.12, while Veru reported a GAAP EPS of -$0.13, which beat expectations by $0.15.

Immunic has announced that it has successfully regained compliance with the Nasdaq Stock Market's minimum bid price requirement.

Immunic, a biopharmaceutical company, has successfully secured $400 million in funding to advance its late-stage clinical trials for Multiple Sclerosis (MS) treatments.

Immunic has closed a $200 million private placement to fund late-stage multiple sclerosis trials, securing significant capital for its research and development.

Immunic, a biopharmaceutical company, has appointed Mike Bonney, a veteran from Biogen and Cubist, as its new board chair. The appointment comes ahead of a key multiple sclerosis (MS) trial readout.

Immunic has announced a 1-for-10 reverse stock split, while C3is also declared a 1-for-7 reverse stock split. These actions are typically taken to increase a company's share price and meet exchange listing requirements.

Immunic, a biopharmaceutical company, has announced the appointment of biopharmaceutical executive Jon Congleton to its board of directors.

Immunic has secured $400 million in financing, setting the stage for the readout of its phase 3 multiple sclerosis (MS) data.

Biopharmaceutical company Immunic has successfully secured $400 million in funding to advance its commercial-stage development projects.

Immunic has announced advancements in its Phase 3 multiple sclerosis program and anticipates releasing topline data by the end of the year.

Immunic announced an offering of up to 458.2 million shares of common stock registered for resale by selling stockholders, according to an SEC filing.

Immunic has garnered a new 'Buy' rating from Guggenheim, indicating positive analyst sentiment regarding its lead asset.

Immunic has successfully secured $400 million in funding to support the commercial-stage development of its projects. This capital injection will aid in advancing its pipeline.